Drug Trial Radar · NCT02156739
Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Actual
Start
Oct 13, 2014
Primary completion
Jun 1, 2028
Study completion Jun 1, 2028
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 5, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, may help doctors to see MRI images more clearly.
Conditions
- Hepatocellular Carcinoma
- Liver and Intrahepatic Bile Duct Disorder
- Metastatic Malignant Neoplasm in the Liver
- Primary Malignant Liver Neoplasm
Interventions
Contrast-enhanced Magnetic Resonance ImagingProcedure
Undergo contrast-enhanced MRI
GadobutrolDrug
Given IV
Gadoxetate DisodiumDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Specificity of combining gadoxetate disodium and gadobutrol in diagnosing tumor lesions radiologically using magnetic resonance imaging (MRI)Time frame: Up to 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
M D Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.